Implantable Drug Delivery Devices Market, by Product Type (Drug Infusion Pumps, Intraocular Drug Delivery Devices, Contraceptive Drug Delivery Devices, and Stents) by Technology (Biodegradable Implants and Non-biodegradable Implants), by Application (Op

Implantable Drug Delivery Devices Market, by Product Type (Drug Infusion Pumps, Intraocular Drug Delivery Devices, Contraceptive Drug Delivery Devices, and Stents) by Technology (Biodegradable Implants and Non-biodegradable Implants), by Application (Ophthalmology, Cardiovascular, Birth Control/Contraception, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Implantable drug delivery devices, also called as implantable drug eluting devices, allow targeted and localized drug delivery once the device is implanted in the body. There are various implantable drug delivery devices available such as vascular stents, electro stimulation devices, orthopedic devices, and others. An implantable device also delivers drugs to the primary site of action, when it is combined with the drugs. Thus, many drug therapies have been developed for hormonal disorders, cardiovascular disorders, oncology, ophthalmology, and others.
There are two types of drug delivery systems: biodegradable and non-biodegradable. Biodegradable drug-eluting devices (also referred to as bioerodible) use biocompatible materials such as polyesteramide (PEA) and Poly Lactic-co-Glycolic Acid (PLGA) to deliver drugs and once implanted, it decomposes over time. On the other hand, non-biodegradable drug-eluting devices (also referred to as biodurable) use biocompatible materials such as silicone rubber (polydimethylsiloxane or PDMS), polyethylene-vinyl acetate (EVA), and thermoplastic polyurethane (TPU) to deliver drugs. Non-biodegradable drug-eluting devices can be refilled with medication (eg, via injection) and the device’s effects are almost immediately reversible upon removal.
Market Dynamics
Increasing product launches is expected to drive the global implantable drug delivery devices market growth over the forecast period. For instance, in 2021, Occular Therapeutics launched Dextenza ophthalmic insert in the U.S. market. Dextenza ophthalmic insert is an ocular insert that is designed to release 0.4 mg of dexamethasone to relieve pain after ophthalmic surgery. It can deliver drugs for up to 30 days after treatment in a physician’s office.
Companies are engaged in receiving approvals from the regulatory authorities for further marketing the products in the global market. For instance, in 2018, United Therapeutics Corporation received the U.S Food and Drug Administration (FDA) approval for the use of Remodulin (treprostinil) injection in the implantable system. In the Remodulin implantable system, the entire delivery system is implanted into the patient’s body and the system is refilled by healthcare professionals at an interval of up to 16 weeks depending on the prescribed dose, by using a syringe needle and through the patient's skin.
Key features of the study:
This report provides an in-depth analysis of global implantable drug delivery devices market, provides market size (US$ 12,015.2 Million), and compound annual growth rate (CAGR 7.7 %) for the forecast period (2022 - 2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global implantable drug delivery devices market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Boston Scientific Corporation, Abbott Laboratories, Medtronic, Merck & Co., Bausch & Lomb Inc., Allergan, Inc., Psivida Corp., Bayer Healthcare, Alimera Sciences, Eyepoint Pharmaceuticals, Valeant Pharmaceuticals, DSM Biomedical, Delpor Inc., Teleflex Incorporated, and 3M Company
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global implantable drug delivery devices market report caters to various stakeholders in this industry including investors, suppliers, implantable drug delivery device manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the implantable drug delivery devices market
Detailed Segmentation:
Global Implantable Drug Delivery Devices Market, By Product Type:
Drug infusion pumps
Intraocular drug delivery devices
Contraceptive drug delivery devices
Stents
Global Implantable Drug Delivery Devices Market, By Technology:
Biodegradable Implants
Non-biodegradable Implants
Global Implantable Drug Delivery Devices Market, By Application:
Ophthalmology
Oncology
Cardiovascular
Birth control/Contraception
Others
Global Implantable Drug Delivery Devices Market, By Region:
North America
By Country
U.S.
Canada
By Product Type:
Drug infusion pumps
Intraocular drug delivery devices
Contraceptive drug delivery devices
Stents
By Technology
Biodegradable Implants
Non-biodegradable Implants
By Application
Ophthalmology
Oncology
Cardiovascular
Birth control/Contraception
Others
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Product Type:
Drug infusion pumps
Intraocular drug delivery devices
Contraceptive drug delivery devices
Stents
By Technology
Biodegradable Implants
Non-biodegradable Implants
By Application
Ophthalmology
Oncology
Cardiovascular
Birth control/Contraception
Others
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Product Type:
Drug infusion pumps
Intraocular drug delivery devices
Contraceptive drug delivery devices
Stents
By Technology
Biodegradable Implants
Non-biodegradable Implants
By Application
Ophthalmology
Oncology
Cardiovascular
Birth control/Contraception
Others
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Product Type:
Drug infusion pumps
Intraocular drug delivery devices
Contraceptive drug delivery devices
Stents
By Technology
Biodegradable Implants
Non-biodegradable Implants
By Application
Ophthalmology
Oncology
Cardiovascular
Birth control/Contraception
Others
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Product Type:
Drug infusion pumps
Intraocular drug delivery devices
Contraceptive drug delivery devices
Stents
By Technology
Biodegradable Implants
Non-biodegradable Implants
By Application
Ophthalmology
Oncology
Cardiovascular
Birth control/Contraception
Others
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Product Type:
Drug infusion pumps
Intraocular drug delivery devices
Contraceptive drug delivery devices
Stents
By Technology
Biodegradable Implants
Non-biodegradable Implants
By Application
Ophthalmology
Oncology
Cardiovascular
Birth control/Contraception
Others
Company Profiles
Boston Scientific Corporation
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Abbott Laboratories
Medtronic, Merck & Co.
Bausch & Lomb Inc.
Allergan, Inc.
Bayer Healthcare
Alimera Sciences
Eyepoint Pharmaceuticals
DSM Biomedical
Delpor Inc.
Teleflex Incorporated
3M Company
“*” marked represents similar segmentation in other categories in the respective section.